Allergy Free

Mumbai, India Founded: 2018 • Age: 8 yrs Listed
Allergy education and management services in healthcare by Sanofi.

About Allergy Free

Allergy Free is a publicly listed company based in Mumbai (India) founded in 2018. Allergy education and management services in healthcare by Sanofi. The company has 2,191 employees. Its website allergyfree.co.in draws about 14 thousand monthly visits. Its Indian entity Sanofi India Limited reported revenue of ₹1,857 Cr. Allergy Free offers products and services including Allergy Information Services and Educational Resources. Its focus areas include Consumer Health, Educational Resources, Information Distribution and Pharmaceuticals.

Company details

Allergies are discussed extensively on the website, covering symptoms, prevention strategies, and side effects across various types such as outdoor, indoor, and childhood allergies. Information on pollution-related risks in India and comparisons with conditions like COVID-19 is included to clarify distinctions. Management techniques, including lifestyle adjustments and diagnostic tools, are outlined to aid in symptom control, while myths and facts are addressed to promote accurate understanding. Resources like FAQs and downloads are made available for comprehensive support.

Key Metrics
  • Market Cap
    ₹7,375 Cr

    SANOFI · NSE

  • Share Price
    ₹3,206.10

    +0.11% today

  • Revenue
    ₹2,013 Cr

    Dec 2024 · +0.9% YoY

  • EBITDA
    ₹453 Cr

    Margin 22.5%

  • Net Profit
    ₹442 Cr

    Dec 2024 · -24.9% YoY

  • P/E (TTM)
    21.0x

    P/B 9.3x

  • ROE
    47.1%

    ROCE 48.0%

  • Debt / Equity
    0.02

    Interest cover 0.4x

  • Employee Count
    2,191

Products & Services of Allergy Free

Allergy Free offers a comprehensive portfolio of products and services, including Allergy Information Services and Educational Resources.

Allergy Information Services
Health Education

Information on allergy symptoms, prevention, and management is offered to assist in handling reactions effectively.

Educational Resources
Information Products

Downloads and tips on allergy myths, facts, and treatments are provided to support better understanding and control of allergies.

Apps and channels of Allergy Free

its YouTube channel AllergyFree India has 2.17K subscribers and 10 videos.

AllergyFree India
YouTube 2.17K subscribers 10 videos Howto & Style
Open channel

Videos from Allergy Free

The most watched videos on Allergy Free's YouTube channel, AllergyFree India (2.17K subscribers). Click a video to play it here.

How to Use Nasal Spray | English
3.6K views
How to Use Nasal Spray | Tamil
85 views
How to use nasal spray | Telugu
63 views
How to Use Nasal Spray | Hindi
51 views

More on AllergyFree India.

Board of directors of Sanofi India Limited (Allergy Free)

Sanofi India Limited is the primary company behind Allergy Free. The board of Sanofi India Limited currently have 9 directors; the longest-serving is Rahul Bhatnagar, appointed in 2020. 45 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Rahul Bhatnagar
DIN 07268064
Director29 Jul 20206 yrs 3 moSanofi India Limited
Vaibhav Vinayak Karandikar
DIN 09049375
Director23 Feb 20215 yrs 8 moSanofi India Limited
Rachid Ayari
DIN 10408699
Whole-time director01 Dec 20232 yrs 11 moSanofi India Limited
Eric Yves Mansion
DIN 10654588
Director03 Jun 20242 yrs 5 moSanofi India Limited
Mahadev Keshav Gawade
DIN 11231316
Whole-time director11 Aug 20251 yr 3 moSanofi India Limited
Deepak Arora
DIN 07495638
Managing Director27 Oct 20251 yrSanofi India Limited
Sudipta Chakraborty
DIN 07166912
Whole-Time Director01 Mar 20268 moSanofi India Limited
Siraj Azmat Chaudhry
DIN 00161853
Director01 Apr 20267 moSanofi India Limited
Rajani Kesari
DIN 02384170
Director01 Apr 20267 moSanofi India Limited

IPO & Listings of Allergy Free

Allergy Free is a publicly listed company on the NSE with ticker symbol SANOFI in India, operating in the Pharmaceuticals sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • Listed onNSE: SANOFI
  • Listed entitySanofi India Limited
  • Exchange sectorPharmaceuticals

Financials of Allergy Free

Exchange-reported figures of Sanofi India Limited, the listed company behind Allergy Free (NSE: SANOFI).

Financial Highlights

Dec 2024 · Consolidated
Revenue
₹2,013 Cr
+0.9% YoY
EBITDA
₹453 Cr
-7.1% YoY
Profit After Tax
₹442 Cr
-24.9% YoY
Net Worth
-
Total Assets
-
Total Debt
-

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsDec 2024Dec 2023
Income statement
Revenue2,0131,996
Revenue growth+0.9%-
EBITDA453488
EBITDA margin+22.5%+24.4%
Profit before tax531767
Net profit442589
Net profit margin+22.0%+29.5%
EPS (₹)179.70262.13
Balance sheet
Cash flow
ParticularsDec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
Revenue515524464511469491515521
Revenue growth (YoY)+9.7%+6.8%-10.0%-2.0%----
Other income13.902.3039.8068.1077.4081.9057.40101
EBITDA11812096.7011099.60114122153
EBITDA margin+23.0%+22.8%+20.9%+21.6%+21.2%+23.1%+23.6%+29.3%
Depreciation9.609.009.009.109.309.209.108.90
Interest0.400.400.400.300.400.300.700.30
Profit before tax122113127169167186169244
Tax30.9030.4023.9032.5029.6034.0046.3053.90
Net profit91.3082.20103137138152123190
EPS (₹)39.6435.6944.8159.3159.7965.9553.370.00
MetricsDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income statement
Revenue1,8372,0132,8512,7702,9572,9023,071
Revenue growth-8.7%-29.4%+2.9%-6.3%+1.9%-5.5%-
EBITDA464453804704762671606
EBITDA margin+25.3%+22.5%+28.2%+25.4%+25.8%+23.1%+19.7%
Profit before tax4455318468641,258677600
Net profit346442591526581508452
Net profit margin+18.9%+22.0%+20.7%+19.0%+19.7%+17.5%+14.7%
EPS (₹)142.04179.78262.26269.83410.61207.65180.09
Balance sheet
Cash flow
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue492438472420475406536515
Revenue growth (YoY)+3.4%+7.7%-11.9%-18.5%-9.3%-12.3%--
Other income5.506.204.402.804.908.703.3013.90
Total expenses330322330330368311364397
EBITDA16111514390.3010794.90172118
EBITDA margin+32.8%+26.3%+30.2%+21.5%+22.5%+23.4%+32.1%+23.0%
Depreciation8.808.909.009.509.109.109.609.60
Interest0.200.300.300.600.400.400.300.40
Profit before tax15811213883.0010294.10165122
Tax41.0028.8035.3021.3026.3024.6045.8030.90

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 22 Nov 2026
ParticularsDec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
Revenue515524464511469491515521
Revenue growth (YoY)+9.7%+6.8%-10.0%-2.0%----
Other income13.902.3039.8068.1077.4081.9057.40101
EBITDA11812096.7011099.60114122153
EBITDA margin+23.0%+22.8%+20.9%+21.6%+21.2%+23.1%+23.6%+29.3%
Depreciation9.609.009.009.109.309.209.108.90
Interest0.400.400.400.300.400.300.700.30
Profit before tax122113127169167186169244
Tax30.9030.4023.9032.5029.6034.0046.3053.90
Net profit91.3082.20103137138152123190
EPS (₹)39.6435.6944.8159.3159.7965.9553.370.00
ParticularsDec 2024Dec 2023
Revenue2,0131,996
Revenue growth+0.9%-
Other income116317
Total expenses1,5601,508
Employee cost240281
EBITDA453488
EBITDA margin+22.5%+24.4%
Depreciation36.7036.50
Interest1.501.70
Profit before tax531767
Tax118164
Net profit442589
Net profit margin+22.0%+29.5%
EPS (₹)179.70262.13
ParticularsDec 2024Dec 2023
Growth
Sales growth+0.9%-
EBITDA growth-7.1%-
PBT growth-30.8%+9997.0%
Net income growth-24.9%-
Profitability & leverage
Net income margin+20.5%+30.2%
Return on capital employed+48.0%+48.1%
Return on net worth+47.1%+58.0%
Debt / equity0.020.02
Long-term debt / equity0.010.01
Interest cover0.360.38
Efficiency & per share
Fixed asset turnover3.653.67
Inventory turnover3.463.01
Debtors turnover11.1315.16
EPS (₹)179.70262.13
Dividend per share (₹)117.00167.00
Book value per share (₹)374.17441.39
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue492438472420475406536515
Revenue growth (YoY)+3.4%+7.7%-11.9%-18.5%-9.3%-12.3%--
Other income5.506.204.402.804.908.703.3013.90
Total expenses330322330330368311364397
EBITDA16111514390.3010794.90172118
EBITDA margin+32.8%+26.3%+30.2%+21.5%+22.5%+23.4%+32.1%+23.0%
Depreciation8.808.909.009.509.109.109.609.60
Interest0.200.300.300.600.400.400.300.40
Profit before tax15811213883.0010294.10165122
Tax41.0028.8035.3021.3026.3024.6045.8030.90
ParticularsDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Revenue1,8372,0132,8512,7702,9572,9023,071
Revenue growth-8.7%-29.4%+2.9%-6.3%+1.9%-5.5%-
Other income19.7011683.1020456489.8094.10
Total expenses1,3731,5602,0472,0662,1942,2302,465
Employee cost185240371406434461450
EBITDA464453804704762671606
EBITDA margin+25.3%+22.5%+28.2%+25.4%+25.8%+23.1%+19.7%
Depreciation37.3036.7039.6041.9066.7082.2099.90
Interest1.701.501.701.701.801.800.30
Profit before tax4455318468641,258677600
Tax118118243244313200186
Net profit346442591526581508452
Net profit margin+18.9%+22.0%+20.7%+19.0%+19.7%+17.5%+14.7%
EPS (₹)142.04179.78262.26269.83410.61207.65180.09
ParticularsDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Growth
Sales growth-8.7%-29.4%+2.9%-6.3%+1.9%-5.5%-
EBITDA growth+2.4%-43.6%+14.1%-7.6%+13.6%+10.8%-
PBT growth-16.3%-37.2%-2.1%-31.3%+85.7%+12.9%-1.6%
Net income growth-21.7%-25.1%+12.3%-9.5%+14.3%+12.4%-
Revenue CAGR (3Y)-12.8%-12.0%-0.6%-3.4%+2.2%+5.7%+9.1%
EBITDA CAGR (3Y)-13.0%-15.9%+6.2%+5.1%+6.9%+7.7%+4.2%
Profitability & leverage
Net income margin+17.8%+20.5%+21.2%+22.4%+31.9%+16.5%+13.5%
Return on capital employed+54.2%+48.4%+70.6%+40.3%+33.8%+28.9%+27.8%
Return on net worth+40.6%+47.2%+52.7%+30.1%+26.8%+20.9%+19.4%
Debt / equity0.020.020.020.010.010.000.00
Long-term debt / equity0.020.010.010.010.010.000.00
Interest cover0.400.360.220.260.260.310.06
Efficiency & per share
Fixed asset turnover3.233.655.315.144.233.483.28
Inventory turnover4.533.465.326.927.786.936.45
Debtors turnover9.0411.1321.8620.3720.3315.6016.06
EPS (₹)142.04179.78262.26269.83410.61207.65180.09
Dividend per share (₹)123.00117.00167.00570.00490.00365.00349.00
Book value per share (₹)325.74374.17441.52554.70967.65921.301,061.87

Web traffic of Allergy Free

The website of Allergy Free (allergyfree.co.in) receives about 13.9K visits a month.

  • Monthly visits
    13.9K

    ▼ 25% vs previous month

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Allergy Free

Sanofi: Sanofi Global Raises FY Sales And Business EPS Growth Guidance
Exchange Update • 23 days ago
SANOFI INDIA: CO DECLARES INTERIM DIVIDEND OF 75 RUPEES PER SHR
Exchange Update • 24 days ago
SANOFI: Q2 REVENUE 4.9B RUPEES VS 4.75B (YOY)
Exchange Update • 24 days ago
SANOFI: Q2 SL NET PROFIT 1.16B RUPEES VS 760M (YOY)
Exchange Update • 24 days ago
SANOFI: Q2 EBITDA 1.9B RUPEES VS 1.34B (YOY); Q2 EBITDA MARGIN 39.07% VS 28.23% (YOY)
Exchange Update • 24 days ago
Sanofi Healthcare India: Buys 3.5 Million Shares, 15.20% Of Sanofi India From Hoechst GmbH Through Block Deal; No Change In Promoter Group Ownership.
Exchange Update • 1 month ago
SANOFI: RS 1068.2CR NSE BLOCK TRADE; FOR ~3500000 SHARES, AT RS 3052 (PRE-OPEN)
Exchange Update • 1 month ago
Premium access

Complete news archive for Allergy Free

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Allergy Free

Allergy Free was founded in 2018.

Allergy Free is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Allergy Free has 2,191 employees.

The primary company behind Allergy Free, Sanofi India Limited, reported revenue of ₹1,857 Cr for FY 2025, down 9% year on year.

Allergies are discussed extensively on the website, covering symptoms, prevention strategies, and side effects across various types such as outdoor, indoor, and childhood allergies. Information on pollution-related risks in India and comparisons with conditions like COVID-19 is included to clarify distinctions. Management techniques, including lifestyle adjustments and diagnostic tools, are outlined to aid in symptom control, while myths and facts are addressed to promote accurate understanding. Resources like FAQs and downloads are made available for comprehensive support.

Allergy Free offers Allergy Information Services and Educational Resources.

Yes, Allergy Free is publicly traded on NSE under the ticker symbol SANOFI.

Allergy Free operates through Sanofi India Limited.

The legal entities of Allergy Free currently have 10 directors, including Vaibhav Vinayak Karandikar, Rahul Bhatnagar, Deepak Arora and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available